SoftOx Solutions AS (SOFTX.OL)

0.1800 +0.0135 (+8.11%) As of 02:27PM CEST. Market open.

SoftOx Solutions AS

Martin Linges vei 25
Fornebu 1364
Norway
47 94 85 95 99
https://soft-ox.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7

Description

SoftOx Solutions AS, together with its subsidiaries, operates as a medtech and clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. Its products include SafeDes+, a hand disinfectant for irritated, compromised, and eczematous skin; and EffectDesH, a surface disinfectant, which has a killing/inactivation effect on bacteria, viruses, yeast, fungi, mycobacterium, and spores. The company also provides human wound and infection treatment products comprising SoftOx Wound Irrigation solutions for acute and chronic wounds to prevent and treat infections, including biofilms; and SoftOx Anti-infectives to treat and remove topical infections in wounded and mucosal tissues, such as biofilms, AMR microbes, viruses, and fungi. In addition, it is developing antiseptic solutions for pets and livestock; and inhalation solution, a novel and self-administered inhaled drug that is in Phase II clinical trial for early treatment and prevention of influenza-like illnesses. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norway.

Corporate governance

SoftOx Solutions AS’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.